MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas. Under the terms ...
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback